MG
BTAI icon

Michael Gelband’s BioXcel Therapeutics BTAI Stock Holding History

Michael Gelband’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,665
Closed -$352K – 1898
2022
Q2 		$352K Buy
+1,665
New +$350K ﹤0.01% 1472
2022
Q1 		– Sell
-656
Closed -$213K – 2214
2021
Q4 		$213K Buy
+656
New +$281K ﹤0.01% 1802
2020
Q4 		– Sell
-365
Closed -$253K – 1984
2020
Q3 		$253K Buy
+365
New +$274K 0.01% 1369

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Michael Gelband's BTAI Position: Q3 2022 in Review

Michael Gelband sold out of BioXcel Therapeutics (BTAI) in Q3 2022, closing a stake of 1,665 shares — an estimated $352K sold.

Michael Gelband first reported a position in BTAI in Q3 2020 and held it in 3 quarters. The position peaked at $352K in Q2 2022. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2022.

  • Michael Gelband reported no remaining BioXcel Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Michael Gelband sold 1,665 BioXcel Therapeutics shares in Q3 2022, an estimated $352K.
  • Michael Gelband first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 3 quarters.
  • Michael Gelband's BioXcel Therapeutics position peaked at $352K in Q2 2022.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.